Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Review of miglustat for clinical management in Gaucher disease type 1

Authors Can Ficicioglu

Published 11 April 2008 Volume 2008:4(2) Pages 425—431

DOI https://doi.org/10.2147/TCRM.S6865

Can Ficicioglu

The Children’s Hospital of Philadelphia, Section of Biochemical Genetics

Abstract: Gaucher disease is a progressive lysosomal storage disorder caused by the deficiency of glucocerebrosidase, and characterized by intralysosomal storage of glucosylceramide that leads to dysfunction in multiple organ systems. Intravenous enzyme replacement with imiglucerase is the accepted standard for treatment of symptomatic patients and has been effective in reducing many of the signs and symptoms of type I Gaucher disease in the majority of patients without serious adverse effects. An alternative therapeutic approach is substrate reduction therapy with N-butyldeoxynojirimycin (NB-DNJ) (miglustat; Zavesca®), an imino sugar that reversibly inhibits glucosylceremide synthase and reduces intracellular storage of glucosylceramide. Miglustat was recently approved in Europe and the United States for symptomatic patients with mild to moderate clinical manifestations for whom enzyme replacement therapy is not an option. This review article discusses the results of clinical studies and use of miglustat as a therapeutic agent in patients with type I Gaucher disease.

Keywords: Gaucher disease, miglustat, substrate reduction therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Screening for medium-chain acyl CoA dehydrogenase deficiency: current perspectives

Soler-Alfonso C, Bennett MJ, Ficicioglu C

Research and Reports in Neonatology 2016, 6:1-10

Published Date: 18 January 2016

Readers of this article also read:

Prediction and prevention of the first psychotic episode: new directions and opportunities

Piras S, Casu G, Casu MA, Orrù A, Ruiu S, Pilleri A, Manca G, Marchese G

Therapeutics and Clinical Risk Management 2014, 10:241-253

Published Date: 28 March 2014

Erratum

Rapidis A, Sarlis N, Lefebvre J-L, et al

Therapeutics and Clinical Risk Management 2008, 4:1381-1381

Published Date: 5 December 2008

Early ischemic CT changes before thrombolysis: The influence of age and diabetes mellitus

Lars Thomassen, Ulrike Waje-Andreassen, Halvor Naess

Therapeutics and Clinical Risk Management 2008, 4:699-703

Published Date: 8 August 2008

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Zinelabidine Abouelfadel, E David Crawford

Therapeutics and Clinical Risk Management 2008, 4:513-526

Published Date: 11 April 2008

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists

Hans P Schlecht, Sarah Schellhorn, Bruce J Dezube, Jeffrey M Jacobson

Therapeutics and Clinical Risk Management 2008, 4:473-485

Published Date: 11 April 2008

Pharmacological causes of hyperprolactinemia

Daria La Torre, Alberto Falorni

Therapeutics and Clinical Risk Management 2007, 3:929-951

Published Date: 15 November 2007

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007

Evaluation of patient care interventions and recommendations by a transitional care pharmacist

K Bruce Bayley, Lucy A Savitz, Teresa Maddalone, Stephen E Stoner, Jacquelyn S Hunt, Robert Wells

Therapeutics and Clinical Risk Management 2007, 3:695-703

Published Date: 15 September 2007

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007